Systems and methods for diagnosing and treating a neurodegenerative disorder in a subject can be used for the diagnosis of Mild Cognitive Impairment, Early Mild Cognitive Impairment, Late Mild Cognitive Impairment, Parkinson's Disease, Dementia or Alzheimer's Disease in a subject, and for the treatment of a subject diagnosed with such neurodegenerative diseases.

Systems and methods for diagnosing and treating a neurodegenerative disorder in a subject can be used for the diagnosis of Mild Cognitive Impairment, Early Mild Cognitive Impairment, Late Mild Cognitive Impairment, Parkinson's Disease, Dementia or Alzheimer's Disease in a subject, and for the treatment of a subject diagnosed with such neurodegenerative diseases.

A method and an system for vaccinating a mammalian subject. The method includes the steps of: arranging a source of electromagnetic radiation proximate to a target zone of skin of the mammalian subject; controlling the source of electromagnetic radiation to deliver a dose of electromagnetic radiation to the target zone determined to create one or more thermally-denatured zones in the target zone; and intradermally injecting a vaccine within the target zone to vaccinate the mammalian subject. The system for vaccinating a subject may include an electromagnetic radiation source configured to be arranged proximate to a target zone on an exterior of the subject; a user control configured to selectively cause the electromagnetic radiation source to deliver a dose of electromagnetic radiation toward the target zone to create one or more thermally-denatured zones in the target zone; and a vaccine-delivery system configured to deliver a vaccine to the target zone.

A method for directing therapeutic nanoparticle-labeled cells to selected locations within the body and/or for retaining therapeutic nanoparticle-labeled cells at selected locations within the body, the method comprising: providing an article comprising a body of material configured to be secured about the body of a patient and having a plurality of pockets thereon, wherein each pocket is sized to receive and retain one or more magnets therein; injecting therapeutic USPIO nanoparticle-containing cells into a target therapy site; securing the article to the body of the patient; and inserting at least one magnet into at least one pocket so as to provide a desired magnetic field for further directing therapeutic nanoparticle-labelled cells to a target therapy site and/or for retaining therapeutic nanoparticle-labeled cells at the target therapy site.

A method for directing therapeutic nanoparticle-labeled cells to selected locations within the body and/or for retaining therapeutic nanoparticle-labeled cells at selected locations within the body, the method comprising: providing an article comprising a body of material configured to be secured about the body of a patient and having a plurality of pockets thereon, wherein each pocket is sized to receive and retain one or more magnets therein; injecting therapeutic USPIO nanoparticle-containing cells into a target therapy site; securing the article to the body of the patient; and inserting at least one magnet into at least one pocket so as to provide a desired magnetic field for further directing therapeutic nanoparticle-labelled cells to a target therapy site and/or for retaining therapeutic nanoparticle-labeled cells at the target therapy site.

Provided herein are nanoparticle-lipid composite carriers as theranostic agents, particularly for diagnosis and/or treatment of cancers and related diseases and conditions. In particular embodiments, the carrier composites comprise a lipid core and an outer shell of functionalized nanoparticles (fNPs).

A system for reducing toxicity from intravascular triggered drug delivery includes a chamber comprising an inflow port, an outflow port, and a filter positioned upstream of the outflow port. A trigger module is configured to trigger the release of a drug from an intravascular triggered drug delivery system present in blood in the chamber. A method for reducing toxicity from intravascular triggered drug delivery includes the steps of removing blood comprising an intravascular triggered drug delivery system from a patient's vascular system and delivering the blood to a chamber, applying a trigger to the blood to release a drug from the intravascular triggered drug delivery system, filtering the drug from the blood, and returning the filtered blood to the patient.

The present invention relates to small cationic ortho-5,15-di-heteroaryl porphyrin derivatives, in particular porphyrins, chlorins or bacteriochlorin of formula (I) or pharmaceutically acceptable salts thereof.

This invention also relates to the use of the above-mentioned cationic ortho-5,10-di-heteroaryl porphyrin derivatives of Formula (I) or a pharmaceutically acceptable salts thereof, in photodynamic inactivation of microorganisms, where the referred derivatives are able to treat the same in the presence of an adequate light.

The present invention also describes pharmaceutical compositions comprising one or more of the cationic ortho-5,10-di-heteroaryl porphyrin derivatives, in particular prophyrins, chlorins or bacteriochlorins of Formula (I), or pharmaceutically acceptable salts thereof, for the treatment of bacterial and/or fungi and/or yeasts and/or viral infections, in humans or animals.

Disclosed are visible light-activatable antitumor self-assembled nanoparticles or antitumor immunity-inducing self-assembled nanoparticles. The self-assembled nanoparticles induce potent apoptosis in cancer cells and increase their own anticancer immunogenicity, thereby maximizing their therapeutic efficacy for cancer.

The present invention relates to a polymer composite for ultrasound-based cancer immunotherapy, which comprises an peroxalate derivatives, and a preparation method thereof. The polymer composite according to the present invention is a structure in which the peroxalate derivatives are encapsulated in an amphipathic polymer compound in which a biocompatible polymer and a sonosensitizer are combined. The peroxalate derivatives produce free electrons and carbon dioxide (CO.sub.2) by reaction with a high concentration of hydrogen peroxide (H.sub.2O.sub.2) in cancer tissue, the generated electrons raise the energy level of the sonosensitizer in the polymer composite to increase the amount of reactive oxygen species (ROS) production, thereby exhibiting an effect of increasing the death rate of cancer cells. In addition, by ultrasound treatment, immunogenic cell death (ICD) is induced due to the cavitation effect of the produced CO.sub.2, so molecules capable of activating immune cells in cancer cells are released without damage to induce an immune response to cancer. Therefore, the polymer composite according to the present invention is expected to be effectively used as an ultrasound-based cancer immunotherapeutic agent.